Related Experiment Video
Updated: Feb 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A Deep Dive Into Oncogenic Viruses Understanding Their Role in Cancer and Approaches for Prevention
Neetesh Jindal1, Bipin Bihari Mishra1, Ashish Kumar1
1Department of Virology, ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Abstract:
Oncogenic viruses, including Epstein-Barr virus (EBV), Human Papillomavirus (HPV), Kaposi's Sarcoma-Associated Herpesvirus (KSHV), Hepatitis B Virus (HBV), Merkel Cell Polyomavirus (MCPyV), Human T-cell Lymphotropic Virus (HTLV-1), and Hepatitis C Virus (HCV), are significant contributors to cancer development, each through distinct mechanisms. EBV is recognised for its association with cancers such as Burkitt lymphoma and nasopharyngeal carcinoma. High-risk types of HPV are primarily connected to cervical cancer. KSHV plays a crucial role in the development of Kaposi's sarcoma, especially among individuals with compromised immune systems. Both HBV and HCV are implicated in liver cancer due to chronic infections and resultant inflammation. MCPyV is linked to aggressive skin cancers, while HTLV-1 can lead to leukemia and various neurological complications. Collectively, these viruses account for approximately 20% of all cancers globally, providing valuable insights into cancer pathogenesis and potential treatment avenues. Effective management of these viruses includes the use of vaccines such as Gardasil for HPV and antiviral medications for HBV and HCV. Treatment options for cancers associated with EBV, KSHV, and MCPyV encompass targeted therapies and surgical interventions. Preventive measures emphasise vaccination, safe practices to curb virus transmission, routine screenings, and maintaining a healthy lifestyle. Ongoing research and public health initiatives are vital for enhancing prevention and treatment strategies, particularly in high-risk and resource-limited settings. By deepening our understanding of these viruses, we can improve the development of targeted therapies and strive to reduce the global burden of cancer.
Insights
Oncogenic viruses like EBV and HPV cause about 20% of global cancers. Understanding their distinct mechanisms aids in developing vaccines, antivirals, and targeted therapies for prevention and treatment.
Area of Science:
- Oncology
- Virology
- Infectious Diseases
Background:
- Oncogenic viruses are major contributors to global cancer burden.
- Specific viruses like EBV, HPV, KSHV, HBV, MCPyV, HTLV-1, and HCV drive distinct cancer types through unique mechanisms.
- These viruses collectively account for approximately 20% of all human cancers.
Purpose of the Study:
- To elucidate the diverse mechanisms by which oncogenic viruses contribute to cancer development.
- To highlight the global impact of viral oncogenesis and identify key viruses involved.
- To review current and potential strategies for the prevention and treatment of virus-associated cancers.
Main Methods:
- Review and synthesis of existing literature on oncogenic viruses and their associated cancers.
- Analysis of the specific pathogenic roles of EBV, HPV, KSHV, HBV, MCPyV, HTLV-1, and HCV.
- Examination of current therapeutic and preventive strategies, including vaccines and antiviral medications.
Main Results:
- Epstein-Barr virus (EBV) is linked to Burkitt lymphoma and nasopharyngeal carcinoma.
- High-risk Human Papillomavirus (HPV) types are primarily associated with cervical cancer.
- Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are implicated in liver cancer.
- Kaposi's Sarcoma-Associated Herpesvirus (KSHV) is crucial in Kaposi's sarcoma development.
- Merkel Cell Polyomavirus (MCPyV) is linked to aggressive skin cancers.
- Human T-cell Lymphotropic Virus (HTLV-1) can cause leukemia and neurological issues.
- Collectively, these viruses cause about 20% of all cancers worldwide.
Conclusions:
- Oncogenic viruses represent a significant and preventable cause of cancer.
- Vaccination (e.g., HPV), antiviral therapies (e.g., HBV, HCV), targeted treatments, and lifestyle modifications are key preventive and management strategies.
- Continued research and public health initiatives are essential for reducing the global burden of virus-associated cancers, especially in resource-limited settings.
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Cancer Prevention
Some...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

